Roth Capital says Cinemark strong start to Q2 has reversed Q1 downturn

Following Q1 results, Roth Capital analyst Eric Handler told investors in a research note that Cinemark (CNK) is as an attractive, defensive asset that is just entering the start of what should be a two year plus positive content cycle. As the box office grows, margins should expand and cash flow should increase, thereby creating the potential for a higher level of capital returns, the firm added. Roth Capital reiterates a Buy rating and $36 price target on Cinemark shares.